GSK Plans To Stop Further Development Of Camlipixant In Refractory Chronic Cough As Camlipixant 25mg Twice Daily Failed To Meet Statistical Significance In CALM-1, CALM-2 Clinical Trials
https://www.gsk.com/en-gb/media/press-releases/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials/
Why It Matters
GSK's new cough medicine didn't work as well as hoped in testing, so the company is stopping its development. When a medicine fails its tests, it tells us the company's research isn't moving forward as planned, which investors watch carefully.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.